Neuromodulation: Technology at the Neural Interface
© International Neuromodulation Society
Edited By: Robert Levy, MD, PhD
Impact Factor: 1.186
ISI Journal Citation Reports © Ranking: 2011: 80/112 (Medicine Research & Experimental); 151/192 (Clinical Neurology)
Online ISSN: 1525-1403
Online Manuscript Submission
Authorship and Contributorship
Conflicts of Interest Disclosures
Informed Consent and Ethical Approval of Studies
Obligation to Register Clinical Trials
Abstract Page with Key Words/Phrases
Printed Author Offprints
Duplicate Publication and Scientific Fraud
English-Language Editing Services
Early View Publication
Neuromodulation: Technology at the Neural Interface, the official journal of the International Neuromodulation Society (INS), is a peer-reviewed, bimonthly publication published by Wiley-Blackwell. Robert M. Levy, M.D., Ph.D., is the Editor-in-Chief, and the Editorial Office is based in Jacksonville, Florida, U.S.A. The Section Editors and Editorial Board consist of carefully selected experts from around the world and from various disciplines reflecting the diverse nature of the field of neuromodulation.
As the preeminent journal in this field, Neuromodulation provides our readership with state of the art clinical, translational, and basic science research in the field. For clinicians, engineers, researchers, allied health professionals, educators, students, administrators, policy makers and members of the biotechnology industry alike, Neuromodulation provides timely and rigorously peer-reviewed articles on the technology, science, and clinical application of devices that interface with the nervous system to treat disease and improve function. Representing the needs of the broad neuromodulation community and beyond, the journal serves as an instrument for the exchange of high quality data aimed at improving results, and advancing science, and as a forum for debate and commentary.
Neuromodulation covers an ever expanding field including, pain, headache, movement disorders, spasticity, paralysis, psychiatric disorders, epilepsy, sensory deprivation, cardiovascular disorders, gastric dysfunction, obesity, and incontinence. In-depth reviews, clinical research, basic research, case reports, technical notes, topical editorials, national and international meeting abstracts, special focus editions, and web-based educational offerings help our reader to expand their knowledge and understanding of the interface between electrical and chemical modulation of the nervous system and the patient. Each issue of Neuromodulation includes two recurring columns. Neurotechnology Reports keep the reader informed of the rapidly changing landscape of the business of neuromodulation, while the Science Times articles highlight key research published in areas outside of Neuromodulation that are of interest to our readership. Neuromodulation also publishes updates on past and future news of events and activities of the INS, and its membership, to keep the reader abreast of issues related to professional education and development in this dynamic field.
Neuromodulation: Technology at the Neural Interface is a rigorously peer-reviewed journal. Upon submission, each manuscript undergoes a preliminary review by the Editor-in-Chief and, if the submission is felt to be appropriate for Neuromodulation, the Editor assigns the manuscript to a Section Editor, based upon subject matter.
The Section Editors are responsible for selecting at least three reviewers for each manuscript, for refereeing the peer review process, and for giving their informed recommendations to the Editor-in-Chief. The Editor-in-Chief then makes the final decision on the manuscript. All manuscripts are peer reviewed for appropriateness for Neuromodulation, originality of content, scientific merit and significance, clarity of presentation, and methods, when appropriate. The peer review process is double-blinded. Selected reviewers remain anonymous to the author(s) of the submission, and the author(s) identities are blinded to the reviewers.
The possible recommendations of the reviewers include “publish without revision”, “minor revision”, “major revision” and “reject”, on the grounds recommended by the reviewers and Section Editor. All manuscripts that are not accepted for publication are returned to the authors with the reviewers’ and editors’ recommendations for revising or rewriting the manuscript. Authors are instructed to address and respond in detail to each review and to track their edits within their revised manuscript. Upon receipt of the revised manuscript, the Editorial Office sends it to the original Section Editor and reviewers for review.
Manuscripts are accepted for publication only when the authors satisfy the concerns and suggestions of reviewers and the Editors and meet the scientific and editorial standards of Neuromodulation.
Public Commentary: All reviewers are asked to submit a public commentary that will be included at the end of all published articles. For examples of previously published commentaries, please visit: SAMPLE COMMENTARIES.docx.
Conflict of Interests: Journal editors, editorial board members, and peer reviewers are asked to withdraw from the review or decisions about manuscripts in which any circumstances might prevent them from offering unbiased editorial decisions. For information regarding the responsibilities and rights of editors and reviewers, please refer to The Council of Science Editors' "Editorial Policy Statements" to which Neuromodulation subscribes. http://www.councilscienceeditors.org.
Neuromodulation invites comment and dissenting opinion on any and all Editorials and manuscripts that it publishes. All opinions and comments regarding published material in Neuromodulation will be published as “Letters to the Editor.” All “Letters to the Editor” regarding a published article or Editorial will be sent to the original author of the article or Editorial for rebuttal and published with the letter. Please email Editorial letters to the editor to firstname.lastname@example.org.
Online Manuscript Submission
Hard-copy submissions will not be accepted. All manuscripts must be submitted online through ScholarOneTM Manuscripts at: http://mc.manuscriptcentral.com/ner
Instructions for using the online submission system are available at: http://mchelp.manuscriptcentral.com/gethelpnow/index.html
If you are a new user, please click on “Register here” at http://mc.manuscriptcentral.com/ner. Upon successful registration, you will be sent an email containing your username and password and instructions for logging into the ScholarOneTM system. Please save or print a copy of this information for future reference.
Returning users, please log in to the site at http://mc.manuscriptcentral.com/ner, and enter the “Author Center” to submit a new manuscript, continue with a previously started submission or check the status of a manuscript undergoing review. You will be able to track the progress of your manuscript through the system. If you have any questions or experience problems, please email email@example.com or call 1 312 388 7388 for assistance.
Authorship and Contributorship
Neuromodulation: Technology at the Neural Interface bases its authorship criteria on those outlined by the International Committee of Medical Journal Editors’ (ICMJE) Uniform Requirements for Manuscripts Submitted to Biomedical Publications. (http://www.icmje.org/ethical_1author.html)3 The corresponding author must submit the manuscript, related files, and all required data and information. From the point of submission until publication, all communication related to the manuscript will be directed to and received from the designated corresponding author only.
Authorship credit should be based on:
1) Substantial contribution to conception and design, or acquisition of data, or analysis and interpretation of data;
2) Drafting the article or reviewing it critically for important intellectual content; and
3) Final approval of the version to be published.3
Corresponding authors are required to complete an Authorship and Contributorship Form upon submission of their manuscripts. Authorship statements will be published with each article. The Authorship Form is available here: http://mc.manuscriptcentral.com/ner
Conflicts of Interest Disclosures
Neuromodulation: Technology at the Neural Interface’s policy on conflict of interest is consistent with that of the International Committee of Medical Journal Editors.3 The journal has a primary responsibility to its readers and to the public to provide in its pages clear and unbiased scientific results and analyses. Although we rely on the expertise of our Editors, Editorial Board members and our peer reviewers to help us accomplish this, we believe that our readers should be informed of additional relationships of our authors that could pose a conflict of interest. Thus, for readers to evaluate the data and opinions presented in this journal, they must be informed of financial and other interests of our authors that may be at odds with unbiased presentation of data or analysis.
Therefore, Neuromodulation requires that all manuscripts be accompanied by clear disclosures from all authors of their affiliations, funding sources, or financial holdings that might raise questions about possible sources of bias.
Disclosure is accomplished in three ways:
1) By a complete listing of the current institutional affiliations of the authors.
2) Through the acknowledgment of all financial contributions to the work being reported, including contributions “in kind.”
3) Through the execution of a statement disclosing to the Editors all financial holdings, professional affiliations, advisory positions, board memberships, patent holdings and the like that might bear a relationship to the subject matter of the contribution.
The authors must acknowledge any conflict of interest they may have in the submission. The conflicts of interest may fall under any of the following categories:
- Guarantor of the article;
- Specific author contributions;
- Financial support;
- Potential competing interests.
For example, [Name of individual] has received fees for serving as a speaker, a consultant and an advisory board member for [names of organizations], and has received research funding from [names of organization]. [Name of individual] is an employee of [Name of organization]. [Name of individual] owns stocks and shares in [name of organization]. [Name of individual] owns patent [patent identification and brief description]. Conflict of interest statements will be published with each article.3
Informed Consent and Ethical Approval of Studies
When human and nonhuman investigation/experimentation has taken place, manuscripts must state in the Material and Methods section that the appropriate institutional review body or ethics committee granted approval before the study began and that the institutional guidelines were followed.3
It is your responsibility, as the author, to have the proper institutional review board (IRB) approve your research study before submitting your manuscript for publication. Your submission to Neuromodulation must state that you have such approval if your paper describes human subjects or experimental animals. IRB approval should be described in the Materials and Methods section. For those authors who do not have formal ethics review committees, the principles outlined in the Declaration of Helsinki should be followed.4 For investigations of humans, explain in the Materials and Methods section the manner in which informed consent was obtained from the study participants (i.e. written or oral). The type of nonhuman subjects must be stated in the title, abstract, key words, and Material and Methods section of the report. Editors may request documentation of the formal review and recommendation from the institutional review board or ethics committee responsible for oversight of the study.
Identifying information, including patients’ names, initials, or hospital numbers, should not be published in written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and the patient (or parent or guardian) gives written informed consent for publication. Informed consent for this purpose requires that a patient who is identifiable be shown the manuscript to be published.3 Identifying information should be omitted if nonessential, but patient data should never be altered or falsified in an attempt to attain anonymity. Complete anonymity is difficult to achieve, and informed consent should be obtained if there is any doubt.
Obligation to Register Clinical Trials
The ICMJE defines a clinical trial as any research project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause-and-effect relationship between a medical intervention and a health outcome.3 In accordance with the policies of the ICMJE, Neuromodulation requires that all papers submitted to the journal reporting randomized prospective clinical trials be prospectively registered in a registry that is freely available to the public and searchable. Registries accepted by the ICMJE include http://clinicaltrials.gov and the World Health Organization primary registers (http://www.who.int/ictrp/en/). For further information, please refer to the ICMJE website (www.icmje.org).
Manuscripts submitted to Neuromodulation must conform to the guidelines set by the American Medical Association Manual of Style, 10th ed., 2007.2 Requirements for publication are consistent with the International Committee of Medical Journal Editors, which are published in: Uniform Requirements for Manuscripts Submitted to Biomedical Journals, Annals of Internal Medicine 1997; 126:36-47 (www.icmje.org).3
All manuscripts must be submitted in English. Manuscripts must be typed, double-spaced, in US Letter format. Pages should be numbered consecutively in the upper right-hand corner beginning with the Abstract, followed in order by Introductions, Materials and Methods, Results, Discussion, and Conclusion. The title page should be uploaded as a separate document (see below). Manuscripts should be approximately 1,000 to 4,000 words (about 4–16 pages of text), dependent upon the type of report. Simple case reports, without reporting unique outcomes, are to be submitted as “Letters to the Editor”. Case Report Letters should be submitted to Neuromodulation at: http://mc.manuscriptcentral.com/ner. Enter the “Author Center” to submit a new manuscript. Letters to the Editor should not exceed 1,000 words, and a maximum of 3 figures or tables (total). There is no limit on co-authorship or the number of included references in the manuscript.
The title page should include in order (1) the title; (2) the running title, a short version of the title (40 characters or less); (3) authors’ names as they wish them to appear with the first name, middle name, and last name of each author, in that order, followed by each author’s highest academic degree(s); (4) institutional affiliation, city, state, and country in which the study was carried out; (5) source(s) of financial support; (6) authorship statement (7) Conflict of Interest Statement (8) name, address, business and mobile telephone numbers, fax number, and email address, of the corresponding author; (9) name and address of author to whom offprints should be sent (if different from the corresponding author). The title page should be uploaded to ScholarOne™ as a separate document, apart from the body of the manuscript.
Abstract Page with Key Words/Phrases
On page one of the manuscript, the title, and a structured abstract should appear. Beneath the abstract, 3 to 5 key words or short phrases should be listed for indexing purposes. A structured abstract of 250 words or less should accompany full-length articles. The structured abstract should contain four paragraphs with the following headlines: (1) Objectives, stating the hypothesis of the study; (2) Materials and Methods, including the means for problem solving, the subjects (number and relevant characteristics), the intervention studied, and briefly, the statistical analysis; (3) Results, including the outcome of the study and statistical significance; and (4) Conclusions, stating the outcome importance. Authors are encouraged to customize the headlines of the structured abstract to best suit their submitted manuscript. Abstracts are not necessary for letters to the editor, editorials, commentaries, correspondence, opinion pieces, book reviews, or abstracts from meetings.
Key words should appear immediately beneath the abstract and consist of 3 to 5 words or terms used for indexing. It is recommended to use the terms from the medical subject headings of Index Medicus.
Manuscripts should be written in the active voice. Ideas should be expressed briefly, clearly, and concisely. Reports claiming to be a “first of a kind” must be verified as such with the source(s) of the literature searched and the years included in the search. Direct quotations should be enclosed with quotation marks and attributed in full to the author and source, including the exact page numbers. Closely paraphrased material should be referenced within the text, so as to leave no doubt as to the source of the original information.
For drugs, devices, or patented procedures, the generic or common name should be followed in parentheses by the trade name, city, and country of manufacture.
Statistical analysis should specify the tests used and to which portions of the data they were applied, rather than simply listed. If a statistical computer program was used, the program should be identified.
Randomized controlled trials should specifically state the method for randomization.
References cited in the manuscript should be listed as a separate section immediately following the text. Authors must verify all references. Citation style must conform to the guidelines set by the AMA Manual of Style: A Guide for Authors and Editors. 10th ed. New York, NY: Oxford University Press; 2007. 1 Journal abbreviations should be those recognized by Index Medicus. Number references sequentially in the order cited in the text. References cited only in a figure or table are numbered according to their first mention in the text. Do not use personal communications or materials “submitted” or “in preparation” as references. Materials accepted for publication, but not yet published, may be cited followed by “(in press).”
References with seven or more authors should list only the first six followed by “et al.” Journal references should appear in the following order: author(s), title, journal abbreviation, year, volume number (in Arabic numerals), and inclusive pages. Book references are listed by author(s), title, edition (when other than first), volume (when more than one), city, publisher, and year. A chapter in a book should be listed by author(s) of the chapter, title of the chapter, “In:”, editor(s)/authors of the book, title of the book, edition (when other than first), volume (when more than one), city, publisher, year, and inclusive pages of the chapter.
Up to five tables will be printed without charge to the author(s). Tables should be labeled consecutively, using Arabic numerals, and follow the references. The table number should be followed by the table’s title. A table exceeding one page should be headed with the table number followed by “continued” in parentheses, and the table heading. Tables containing special symbols or artwork should be submitted as camera-ready copy.
All illustrations should be numbered sequentially with Arabic numerals, in the order cited in the text. Legends should be labeled by figure number and briefly describe the illustration. There are three preferred formats for digital artwork submission: Encapsulated PostScript (EPS), Portable Document Format (PDF), and Tagged Image Format (TIFF). We suggest that line art be saved as EPS files. Alternately, these may be saved as PDF files at 600 dots per inch (dpi) or better at final size. Tone art, or photographic images, should be saved as TIFF files with a resolution of 300 dpi at final size. For combination figures, or artwork that contains both photographs and labeling, we recommend saving figures as EPS files, or as PDF files with a resolution of 600 dpi or better at final size. More detailed information on the submission of electronic artwork can be found at http://authorservices.wiley.com/bauthor/illustration.asp
Photomicrographs must have internal scale markers (linear scale).
If a figure has been published previously, permission must be received in writing for its use regardless of authorship or publisher. Acknowledgment of the original source must be included at the end of the legend.
If you would like the Editors to consider one of your figures for publication on the journal cover, please indicate this in the appropriate section in the online manuscript submission form.
Color illustrations may be printed at the author’s expense. The fee is $500 for the first illustration and $150 for each subsequent illustration. Wiley-Blackwell will provide a color order form to the author with the page proofs.
Figures reproduced from another publication require accompanying written permissions from the author(s) of the work and the holder of the copyright to the work. Credits detailing the authorship and source of the materials must be included in the legend.
Authors may submit supplemental digital content to enhance the online version of their article. Supporting information may include the following types of content: text, tables, figures, graphics, illustrations, and videos.
Cite and number all supporting information consecutively in the text (e.g. Table S1, S2, Figure S1, S2, etc…), and provide a separate legend for this material. Citations should include the type of material submitted, should be clearly labeled as "Supporting Information," and should provide a brief description of the supplemental content at the end of the manuscript. For example: “Video S1 demonstrates the reduction in dyskinesia in the patient receiving deep brain stimulation.”
Access to these files must be provided with the manuscript at the time of submission as they will be included in the peer review process. The supporting information must be uploaded during the file upload step of manuscript submission.
Unless explicitly stated otherwise on the title page, it will be assumed that the authors require Wiley-Blackwell to host the supporting information. The publisher reserves the right to refuse hosting to any data sets that are determined too large for their servers. If the material is hosted by the author, the author must agree to make the supporting information available free of charge on a permanent website, to which links will be set up from the Neuromodulation online edition.
Supporting information will be published as submitted and will not be corrected or checked for scientific accuracy, typographical errors or functionality. Although hosted on the Wiley Online Library, the responsibility for scientific accuracy and file functionality remains entirely with the authors. A disclaimer will be displayed to this effect with any supporting information published.
Wiley-Blackwell will host supporting information on the Wiley Online Library in the format provided by the author. Wiley-Blackwell will not take responsibility for any specialist software required to view the file, for any upgrades to the file as a result of obsolescent formats, or for any updating of the content. If Wiley-Blackwell is hosting then copyright in the supporting information needs to be assigned to the International Neuromodulation Society as part of the original Copyright Form that governs the parent article.
B) Author responsibility
Wiley-Blackwell recommends that material supporting an article is hosted on a reliable website, such that a link can be made to it from the electronic version of the parent article. It is the responsibility of the author to ensure that the hosting of the material meets this criterion. The author must advise Wiley-Blackwell if the URL of the Web site where the supporting information is located changes. The content of the supporting information must not be altered after the paper has been accepted for publication. Copyright in material hosted in this way need not be assigned to Wiley-Blackwell or the International Neuromodulation Society. Authors are reminded that they are responsible for ensuring that they have the right to publish the material or link to the material online, that publication does not infringe the rights of other parties and that the material is not obscene or libelous.
Page proofs of the article as typeset from the copyedited manuscript and illustration proofs will be forwarded by the publisher to the corresponding author. The corresponding author should return all proofs within 48 hours, limiting corrections to typographical errors or corrections in the presentation of information. Correspondence regarding proofs should be sent directly to the publisher.
Free access to the final PDF offprint of your article will be available via Author Services. Please sign up for Author Services if you would like to access your article PDF offprint upon publication of your paper, and enjoy the many other benefits the service offers. To register, visit http://authorservices.wiley.com/bauthor/.
Authors will be required to assign copyright in their paper to the International Neuromodulation Society. Copyright is a condition of publication and papers will not be passed to the publisher for production unless copyright has been assigned.
Duplicate Publication and Scientific Fraud
Submission of a manuscript to Neuromodulation implies that the content has not been published previously and will not be submitted for publication elsewhere while the manuscript is under review. Neuromodulation considers research results (excluding abstracts and student dissertations) to have already been published if they are publicly available with a fixed content, i.e., content is in an unalterable form, and are citable in any language.
If a report or data, including abstracts, have been published previously by any of the named authors (either in part or in full), a reprint of that report must be submitted with the manuscript under consideration. The corresponding author should inform the Editor of the similarities and differences of the reports. This requirement includes reports in which a few different patients, animal, laboratory experiments or data have been added to an existing publication.
In case of possible scientific misconduct, i.e., suspected fabrication or falsification of data, duplicate publication, or plagiarism, the Editor-in-Chief will attempt to clarify the matter with each of the authors. Should that fail to resolve the situation satisfactorily, the Editor-in- Chief will contact the institution of the corresponding author. The institution should then make an inquiry and report to the Editor-in-Chief. Until the matter is clarified, no papers by any authors on the disputed manuscript will be considered for publication.
According to the National Institutes of Health (NIH) mandate, all papers reporting research funded by the NIH must be submitted to PubMed Central. Neuromodulation requires that authors self-identify as NIH funded. During manuscript submission via ScholarOne™ Manuscripts, the submitting author has the option to indicate if the research was NIH funded. If so, pursuant to the NIH mandate, Wiley-Blackwell will forward the manuscript PubMed Central upon acceptance. As an additional failsafe, Wiley-Blackwell will send all manuscripts that list NIH funding in the acknowledgement section to PubMed Central. PubMed Central will receive the accepted version (not proofread or typeset). The accepted version of the manuscript will become freely available to the public twelve months after the online publication date. For further information, see www.wiley.com/go/nihmandate.
Statements and opinions expressed in the manuscript are those of the author(s) and not necessarily those of the editor(s), publisher or the International Neuromodulation Society (INS). The editor(s) or publisher or INS disclaim any responsibility or liability for such information. The author(s), editor(s), nor publisher guarantee, warrant, nor endorse any product or service advertised in the publication, nor do they guarantee any claim made by the manufacturer of said product or service. Please make every effort to comply with the previously stated requirements. Failure to do so may delay review and subsequent publication in the Journal.
English-Language Editing Services
Authors for whom English is a second language may choose to have their manuscript professionally edited before submission or during the review process. Using such a service may increase the likelihood of an expeditious review of your manuscript. Authors wishing to pursue a professional English language editing service should make contact and arrange payment with the editing service of their choice. For more details regarding the recommended services, please refer to http://authorservices.wiley.com/bauthor/english_language.asp.
____2. Provide an abstract of 250 words or less with appropriate headings.
____3. Include a title for each table and figure and online-only material (a brief, succinct phrase, preferably no longer than 10 to 15 words) and explanatory legend as needed.
____4. Include consent documentation for patient photographs. See the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (www.icmje.org).
____5. In studies with human or nonhuman subjects, include statement of institutional review board approval or waiver.
____6. In clinical trials, indicate in which registry the trial has been registered.
____7. Include permission in writing to reproduce previously published illustrations and tables.
____8. Designate a corresponding author and provide an address, telephone number, fax number, and e-mail address.
____9. Complete the Copyright Assignment Form, Conflict of Interest Disclosure, and Authorship Form for all authors and upload the forms to ScholarOne Manuscripts as supplementary files, not for review. Include the conflict of interest and authorship statements on the title page of the manuscript.
____10. For revised manuscripts, track your edits within the text and document your responses to each of the reviewers’ comments in a separate file.
____11. Submit manuscript, tables, and figures online via ScholarOneTM Manuscripts. http://mc.manuscriptcentral.com/ner
____12. If you are submitting a revision, upload to ScholarOneTM Manuscripts the manuscript (with and without the tracked changes), tables, figures, and the document containing your responses to the original reviews.
Online production tracking is available for your article through Wiley-Blackwell’s Author Services. Author Services enables authors to track their article - once it has been accepted - through the production process to publication online and in print. Authors can check the status of their articles online and choose to receive automated e-mails at key stages of production so they don’t need to contact the production editor to check on progress. Visit http://authorservices.wiley.com/bauthor/ for more details on online production tracking and for a wealth of resources including FAQs and tips on article preparation, submission and more.
OnlineOpen is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With OnlineOpen, the author, the author's funding agency, or the author's institution pays a fee to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. For the full list of terms and conditions, see http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms.
Any authors wishing to send their paper OnlineOpen will be required to complete the payment form available from our website at: https://authorservices.wiley.com/bauthor/onlineopen_order.asp.
Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.
Early View Publication
Neuromodulation is covered by Wiley-Blackwell’s Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled print issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors’ final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article.
Wiley has now partnered with the Copyright Clearance Center’s RightsLink® service RightsLink® is an automated real time online permissions service, available to customers 24 hours a day. RightsLink® will enable customers in just a few short moments to automatically clear, pay for and download a license, for a wide range of authorized re-uses, directly from the article abstract page on Wiley Online Library. The service will be available for around 1,400 journals and will be expanded in due course to include all online content such as o-books and major reference works.
If you receive requests for re-use of articles/material from your journal, please inform the requestor that in the majority of cases, they can quickly and easily clear permissions requests using RightsLink®, as follows:
- Navigate to the abstract page of the article for which you’re requesting permission on Wiley Online Library (www.onlinelibrary.wiley.com)
- Click on the ‘Request Permissions’ link
- Follow the online instructions and select your requirements from the drop down options to obtain a ‘quick quote’
- Create a RightsLink® account to complete and pay for your transaction (if you do not already have one)
- Read and accept our Terms & Conditions and download your license
Please note that a small number of articles will not contain the Request Permissions link.
To request permission for these articles, or for any Wiley or Wiley-Blackwell journal article that is not available on Wiley Online Library or for any requests for permission to use material from a Wiley book, please continue to contact the Rights & Permissions team directly on permissionsUK@wiley.com. At present, the response time for permission requests processed outside of RightsLink® is around 20 working days, however, we are continuing to make every effort to improve our response times.
2. Iverson C, Christiansen S, Flanagin A, et al. AMA Manual of Style: A Guide for Authors and Editors. 10th ed. New York, NY: Oxford University Press; 2007. http://www.amamanualofstyle.com.
3. International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. http://www.icmje.org. Updated 2009.
4. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. http://www.wma.net/en/30publications/10policies/b3/index.html. Updated October 2008.